论文部分内容阅读
自1967年美国Field发现聚肌胞(PolyI∶C)是诱导机体内源性干扰素能力最强的诱导物以来,它在治疗病毒感染性疾病中受到许多人的重视,我国采用PolyI∶C治疗慢性病毒性乙型肝炎(下称慢乙肝)虽已有十多年,但对其疗效评价颇不一致,有的学者认为它在人体内诱生干扰素的量与所用剂量大小、疗程长短及给药途径等因素有关。为了摸索本品对慢乙肝的确切疗效,我们对50例慢乙
Since polyglutamic acid (PolyI: C) was induced by the most powerful inducer of endogenous interferon in the body in 1967, Poly Field has been valued by many people for its treatment of viral infectious diseases. PolyI: C treatment in our country Chronic viral hepatitis B (hereinafter referred to as chronic hepatitis B) although more than a decade, but its evaluation of the effect is quite inconsistent, and some scholars believe that it induced in the human body the amount of interferon and the dose size, duration of treatment and administration Ways and other factors. In order to explore the exact effect of this product on chronic hepatitis B, we slow B on 50 cases